Study guide
14.2 Drug Interactions & the Medically Compromised Patient
NDEB Assessment of Fundamental Knowledge AFK
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 About the AFK & NDEB Equivalency Process 1.2 Format, Scoring, Attempts & Exam-Day Rules 1.3 Official Blueprint Weights & Study Strategy
2 Chapter 1: Head & Neck Anatomy
1.1 Osteology, Fascial Spaces & Odontogenic Spread 1.2 Cranial Nerves Relevant to Dentistry 1.3 Vascular Supply, Lymphatics, TMJ & Mastication
3 Chapter 2: Human Physiology for Dentistry
2.1 Cardiovascular & Respiratory Physiology 2.2 Renal, Endocrine & Acid-Base Physiology 2.3 Neuromuscular Physiology & Salivary Function
4 Chapter 3: Biochemistry, Nutrition & Biomaterials
3.1 Metabolism, Enzymes & Oral Biochemistry 3.2 Vitamins, Minerals & Nutritional Deficiencies 3.3 Biomaterials Science: Properties & Biocompatibility
5 Chapter 4: Oral Histology, Embryology & Growth
4.1 Tooth Development & Oral Embryology 4.2 Enamel, Dentin, Cementum, Pulp & Periodontium Histology 4.3 Craniofacial Growth & Development
6 Chapter 5: Microbiology, Immunology & Cariology
5.1 Oral Microbiome, Pathogens & Biofilms 5.2 Immunology & Hypersensitivity in the Oral Cavity 5.3 Cariology: Etiology, Progression & Prevention Science
7 Chapter 6: Dental Anatomy & Occlusion
6.1 Permanent & Primary Tooth Morphology & Roots 6.2 Eruption Sequences & FDI Numbering 6.3 Occlusion Principles & Angle Classification
8 Chapter 7: Restorative Principles & Direct Materials
7.1 Caries Diagnosis & Operative Principles 7.2 Amalgam, Composite Resin & Glass Ionomer 7.3 Adhesion, Bonding & Pulp Protection
9 Chapter 8: Indirect Restorations & Prosthodontics
8.1 Crowns, Bridges, Onlays & Preparation Design 8.2 Complete Dentures & Removable Partial Dentures 8.3 Occlusion Concepts in Prosthodontics
10 Chapter 9: Implants & Advanced Restorative
9.1 Implant Biology & Osseointegration 9.2 Implant Planning, Prosthetics & Complications 9.3 Clinical Dental Materials Selection & Failures
11 Chapter 10: Oral Medicine — Mucosal Disease
10.1 White, Red & Ulcerative Mucosal Lesions 10.2 Oral Cancer & Premalignant Conditions 10.3 Vesiculobullous & Immune-Mediated Mucosal Disease
12 Chapter 11: Oral Pathology — Hard Tissues
11.1 Cysts of the Jaws 11.2 Odontogenic Tumors 11.3 Bone Pathology & Fibro-Osseous Lesions
13 Chapter 12: Salivary Disease, Systemic Manifestations & Oral Radiology
12.1 Salivary Gland Disease 12.2 Systemic Disease Oral Manifestations 12.3 Radiation Physics & Radiographic Technique 12.4 Radiographic Anatomy, Lesions & Interpretation
14 Chapter 13: Local Anesthesia & Analgesia
13.1 Local Anesthetics & Vasoconstrictors 13.2 Injection Techniques, Failures & Complications 13.3 Analgesics, Anxiolysis & Sedation
15 Chapter 14: Systemic Pharmacology & Medical Emergencies
14.1 Antibiotics & Antimicrobials in Dentistry 14.2 Drug Interactions & the Medically Compromised Patient 14.3 Recognition of Medical Emergencies in the Dental Office 14.4 Emergency Drugs & Management Protocols
16 Chapter 15: Periodontics Foundations
15.1 Periodontal Anatomy & Pathogenesis 15.2 2017 AAP Classification of Periodontal Diseases 15.3 Periodontal Examination & Diagnosis
17 Chapter 16: Periodontal Therapy & Systemic Links
16.1 Nonsurgical Periodontal Therapy 16.2 Surgical Periodontics Basics 16.3 Periodontal–Systemic Relationships
18 Chapter 17: Endodontics
17.1 Pulp Biology & Endodontic Diagnosis 17.2 Canal Morphology & Access Preparation 17.3 Instrumentation, Irrigation & Obturation 17.4 Endodontic Emergencies, Trauma & Retreatment
19 Chapter 18: Oral Surgery, Trauma & Orofacial Pain
18.1 Exodontia Principles & Complications 18.2 Impacted Teeth & Minor Oral Surgery 18.3 Maxillofacial Trauma 18.4 Orofacial Pain, TMD & Dental Emergencies
20 Chapter 19: Orthodontics
19.1 Growth, Development & Orthodontic Diagnosis 19.2 Malocclusion Classification & Treatment Planning 19.3 Appliances, Interceptive & Comprehensive Orthodontics
21 Chapter 20: Pediatric Dentistry
20.1 Behavior Management & Primary Dentition Care 20.2 Pediatric Pulp Therapy 20.3 Pediatric Trauma & Space Management
22 Chapter 21: Geriatric & Special Needs Dentistry
21.1 Geriatric Dentistry Considerations 21.2 Special Needs Patients in Dental Practice
23 Chapter 22: Prevention & Evidence-Based Dentistry
22.1 Fluoride, Sealants & Prevention Strategies 22.2 Epidemiology, Caries Indices & Public Health 22.3 Evidence-Based Dentistry & Biostatistics
24 Chapter 23: Infection Control, Ethics & Jurisprudence
23.1 Infection Control & Sterilization 23.2 Ethics & Professionalism for Canadian Practice 23.3 Jurisprudence, Consent & Clinical Records
25 Chapter 24: Integrated Review & Exam Strategy
24.1 High-Yield Differentials Across Domains 24.2 Case Vignette Reasoning Patterns 24.3 Exam-Day Strategy & Pathway Next Steps (ACJ/NDECC)
14.2 Drug Interactions & the Medically Compromised Patient
Key Takeaways Explain This Topic AI
For warfarin-treated patients, know the recent INR, procedure bleeding risk, and whether the physician wants interruption—many routine dental surgeries proceed without stopping warfarin when INR is in therapeutic range and local hemostasis is optimized.
DOACs (e.g., dabigatran, rivaroxaban, apixaban, edoxaban) have shorter half-lives than warfarin; management hinges on renal function, bleeding risk of the procedure, and timing of the last dose rather than INR values.
Antiresorptive drugs (bisphosphonates, denosumab) and some antiangiogenics raise MRONJ risk—prefer preventive dentistry before therapy, atraumatic technique, and informed consent; risk is higher with IV oncology regimens than typical oral osteoporosis doses.
Pregnancy is not a reason to withhold necessary acute dental care; time elective care preferably in the second trimester, use FDA/label pregnancy awareness for drugs, and avoid elective radiographs/drugs when deferrable—but treat infection aggressively when present.
High-yield interactions include metronidazole/macrolides with warfarin, epinephrine caution in uncontrolled hyperthyroid or with non-selective β-blockers (contextual), and CNS depressant stacking with opioids/sedatives.
Last updated: July 2026
14.2 Drug Interactions & the Medically Compromised Patient
Quick Answer: Screen medical history + drug list every visit. Warfarin: use recent INR and local hemostasis—often continue for routine oral surgery if INR is therapeutic. DOACs: time doses around bleeding risk; INR is not the guide. Bisphosphonates/denosumab: MRONJ risk → prevention, atraumatic surgery, consent. Pregnancy: treat infection; prefer second trimester for elective care; choose drugs with better safety data. Interactions that raise bleeding, sedation, or arrhythmia risk are exam favorites.
Medically compromised care is pure AFK application: identify risk, modify plan, know when to consult, and avoid catastrophic interactions. This section pairs with 14.1 (antibiotics) and with local anesthesia/analgesia chapters for epinephrine and opioid safety.
Systematic Pre-Treatment Screen
Domain What to capture Why it changes dentistry
Cardiovascular MI timing, angina class, HF, hypertension control, valves, stents, IE risk Elective deferral windows, LA/epi limits, prophylaxis
Bleeding Warfarin, DOACs, heparin, antiplatelets, liver disease, hemophilia, thrombocytopenia Hemostasis plan, labs, consult
Endocrine Diabetes (hypoglycemia risk), thyroid, adrenal suppression/steroids Timing, infection risk, stress-dose concepts (selected)
- Respiratory Asthma, COPD, OSA Emergency readiness, sedation caution
- Renal / hepatic Clearance of DOACs, local anesthetics, analgesics Dose adjustment / drug choice
- Bone / oncology Bisphosphonates, denosumab, antiangiogenics, head-neck radiation MRONJ / ORN risk
- Pregnancy / lactation Trimester, drugs, positioning Timing and prescribing
- Allergy / anaphylaxis history True IgE vs intolerance Antibiotic and LA choices
- Immunosuppression Transplant, chemo, HIV, biologics Infection threshold, healing
ASA physical status (I–VI) is a communication tool for anesthesia risk, not a complete medical diagnosis—but AFK expects you to recognize ASA III+ patients need tighter modification and possible physician input.
Anticoagulant Management: Warfarin and INR
Warfarin inhibits vitamin K–dependent clotting factors (II, VII, IX, X, proteins C/S). Effect is monitored with INR (international normalized ratio).
Concept AFK teaching
Therapeutic INR (many indications) Often ~2.0–3.0; mechanical mitral valves may target higher (e.g., ~2.5–3.5)—know that targets are indication-specific
Before invasive dental surgery Obtain a recent INR (commonly within 24–72 hours of the procedure in many protocols when values are unstable; stable patients may have a recent clinic value—exam emphasizes “know the INR,” not fly blind)
Routine extractions / minor oral surgery Many guidelines support continuing warfarin when INR is within therapeutic range (often cited comfort zone ≤~3.0–3.5 for simple surgery—follow local protocol) with local measures
Local hemostasis Atraumatic technique, gelatin sponge, sutures, tranexamic acid mouthwash (where used), pressure, avoid NSAIDs that add bleeding risk
When to consult / modify INR supratherapeutic, complex surgery, poor local control expected, concurrent antiplatelets, liver disease
Do not Empirically stop warfarin without a plan—bridging with heparin is a physician decision for selected high-thrombotic-risk patients
High-yield interactions that raise INR / bleeding with warfarin: metronidazole, macrolides (esp. erythromycin/clarithromycin), azole antifungals, some fluoroquinolones, amiodarone, acute alcohol binge, dietary vitamin K swings. NSAIDs add antiplatelet/gastric bleeding risk even if INR unchanged.
AFK stem pattern: patient on warfarin for atrial fibrillation, INR 2.4 yesterday, needs simple extraction → proceed with local hemostasis, usually without stopping warfarin—not automatic hospital admission.
DOACs (Direct Oral Anticoagulants)
DOACs include dabigatran (direct thrombin inhibitor) and rivaroxaban, apixaban, edoxaban (factor Xa inhibitors). They have rapid onset, shorter half-lives than warfarin, and no routine INR monitoring (INR is not a valid intensity guide).
Management principle Detail
Low bleeding-risk procedures Often continue DOAC or time dental work at trough (skip morning dose for some same-day plans per local guidance)
Higher bleeding-risk oral surgery Hold DOAC for a drug-specific interval based on renal function and bleeding risk—coordinate with prescriber
Restart Usually 24–72 h after adequate hemostasis, sooner/later depending on thrombotic vs bleeding balance
Reversal awareness Idarucizumab (dabigatran); andexanet alfa (Xa inhibitors) in hospital emergency settings—not a chairside dental drug
Avoid Adding unnecessary NSAIDs; poor communication about last dose time
Exam contrast table:
- Feature Warfarin DOAC
- Monitor INR Generally none routinely
- Onset/offset Slow (days) Faster (hours)
- Diet vitamin K Yes interaction Minimal
- Renal importance Moderate High for dosing/hold times (esp. dabigatran)
- Dental key Recent INR + local control Timing of last dose + renal + procedure risk
- Antiplatelet Therapy (Aspirin, Clopidogrel, etc.)
Patients with coronary stents, ACS history, or stroke prevention may take aspirin , P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor), or dual antiplatelet therapy (DAPT).
- Principle Teaching
- Do not stop DAPT early after stenting without cardiology—stent thrombosis can be fatal
- Most minor dental surgery Proceed with local hemostasis while continuing antiplatelets
- Aspirin alone Rarely stopped for simple extractions
NSAIDs Add bleeding and cardiac considerations; prefer acetaminophen when antiplatelet/anticoagulant burden is high
Bisphosphonates, Denosumab, and MRONJ
Medication-related osteonecrosis of the jaw (MRONJ) is exposed bone in the maxillofacial region persisting >8 weeks in a patient treated with antiresorptive or antiangiogenic agents, without history of radiation to the jaws (ORN is the radiation analog).
- Risk factor Relative impact
- IV bisphosphonates / denosumab for malignancy Highest risk
- Oral bisphosphonates for osteoporosis Lower absolute risk, still real—duration matters
- Tooth extraction / dentoalveolar surgery Major local trigger
- Infection, ill-fitting dentures, periodontitis Contribute
- Concomitant steroids, antiangiogenics, smoking, diabetes Raise risk
- Clinical approach (AFK)
Prevention: complete urgent dental care before starting IV antiresorptives when possible; optimize hygiene; avoid elective extractions during high-risk therapy when alternatives exist.
If extraction unavoidable: informed consent for MRONJ, atraumatic technique, primary closure when feasible, chlorhexidine, close follow-up; consider drug holiday only with prescribing physician—not a unilateral dental decision.
Established MRONJ: infection control, chlorhexidine, antibiotics when infected, conservative sequestrectomy vs more extensive surgery per stage; specialist referral.
Implants: caution and shared decision-making in antiresorptive users—not automatic absolute ban in low-risk oral osteoporosis, but risk counseling required.
Drug holiday myth: stopping oral bisphosphonates briefly does not instantly restore bone physiology; decisions are individualized with the physician.
Pregnancy: Care Timing and Drug Awareness
Pregnancy is a physiologic stress state—not a reason to neglect odontogenic infection (infection and pain harm mother and fetus more than properly delivered dental care).
- Topic Practical rule
- Elective care Prefer second trimester
- Urgent/emergent care Any trimester—treat infection, abscess, trauma
- Positioning Avoid prolonged supine hypotension in late pregnancy (left lateral tilt)
- Radiographs Use when diagnostic need exists; lead apron + thyroid collar; do not withhold necessary images
Local anesthetics Lidocaine with epinephrine commonly considered acceptable when indicated; aspirate; minimize dose
Analgesics Acetaminophen generally preferred; NSAIDs avoid especially third trimester (ductus arteriosus concerns); opioids only if necessary short-term
Antibiotics Penicillins and cephalosporins generally favored when needed; metronidazole caution especially early; tetracyclines contraindicated (tooth discoloration, bone effects)
- Sedation/N2O Minimize; consult obstetric context for elective use
- Pregnancy drug awareness (historical FDA categories → modern PLLR labeling)
Older FDA letter categories (A, B, C, D, X) still appear in exam teaching even as labels move to narrative Pregnancy and Lactation Labeling Rule (PLLR) language. Use categories as a risk communication shorthand , not a substitute for current product monographs:
- Legacy category Meaning (classic teaching) Dental examples (generalized)
- A Adequate human data, no demonstrated risk Few drugs
- B Animal OK / limited human concern Many penicillins, lidocaine often taught here
- C Animal risk or no studies; use if benefit > risk Some common drugs fall here
D Human risk evidence; reserve for life-threatening need Some anticonvulsants, etc.
X Contraindicated in pregnancy Warfarin (except rare mechanical-valve scenarios under specialist care), isotretinoin, etc.
AFK attitude: choose drugs with the best pregnancy safety record; treat infection; coordinate with obstetric provider for complex cases.
Other High-Yield Medical Modifications
Condition Dental modification
Uncontrolled hypertension / recent MI Defer elective care; limit epinephrine; stress reduction; emergency drugs ready
- Asthma Patient brings inhaler; avoid triggers; careful NSAIDs in sensitive asthmatics
- Diabetes Morning appointments after usual meals/meds; source control for infection; watch hypoglycemia
Adrenal suppression (chronic steroids) Rare need for supplemental steroids for minor dentistry; major surgery/stress may need physician plan
- Liver disease Bleeding risk, altered drug metabolism; avoid excess acetaminophen/hepatotoxins
- CKD Dose-adjust renally cleared drugs; DOAC timing critical
- Hyperthyroidism uncontrolled Avoid elective care; epinephrine caution
- Radiation to jaws ORN risk with extractions—specialist pathways, HBO historically debated
- Drug–Drug Interaction Table (Dental Core)
- Combination Risk
- Warfarin + metronidazole / macrolides / azoles ↑ INR, bleeding
- DOAC + strong P-gp/CYP modulators ↑ or ↓ anticoagulant effect (drug-specific)
Epinephrine + nonselective β-blockers Possible exaggerated BP rise / reflex bradycardia (theoretical/clinical caution with large epi doses)
- Epinephrine + TCA / cocaine Arrhythmia risk—caution/avoid excess
- Opioids + benzodiazepines / alcohol Respiratory depression
- NSAIDs + anticoagulants/antiplatelets Bleeding; GI ulcer
- Macrolides/azoles + midazolam ↑ sedation (CYP3A4)
- SSRI + tramadol Seizure / serotonin syndrome risk
- Rapid review list
- Warfarin: recent INR + local hemostasis; often continue for simple surgery if therapeutic
- DOAC: timing and kidneys, not INR
- Never casually stop post-stent DAPT
- MRONJ: antiresorptives + surgery/infection; prevention first
- Pregnancy: treat infection; second trimester elective; tetracyclines out
- Metronidazole–warfarin and sedative stacking are classic interaction traps
Section 14.3 trains recognition of medical emergencies that these compromised patients are more likely to experience in the chair.